Derek Archila Analyst PerformanceManaging Director, Biotechnology Equity Research at Wells Fargo & CompanyDerek Archila is a stock analyst at Wells Fargo & Company in the medical sector, covering 48 publicly traded companies. Over the past year, Derek Archila has issued 85 stock ratings, including strong buy, buy, and hold recommendations. While full access to Derek Archila's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Derek Archila's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings232 Last 9 YearsBuy Recommendations67.10% 155 Buy RatingsCompanies Covered48 Unique Companies Ratings Distribution231RatingsDistribution of strong buy, buy, hold, and sell ratings by Derek Archila.RatingPercentageCount Strong Buy0.9%2 ratings Buy66.2%153 ratings Hold32.9%76 ratings Sell0.0%0 ratingsOut of 231 total stock ratings issued by Derek Archila at Wells Fargo & Company, the majority (66.2%) have been Buy recommendations, followed by 32.9% Hold and 0.9% Strong Buy.Best & Worst CallsBest Call0000.0%ANABFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ATYRJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.8% of companies on NASDAQ46 companiesNYSE4.2% of companies on NYSE2 companiesDerek Archila, an analyst at Wells Fargo & Company, currently covers 48 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical48 companies100.0%Derek Archila of Wells Fargo & Company specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE38 companies79.2%MED - DRUGS4 companies8.3%MED - GENERIC DRG2 companies4.2%PHARMACEUTICAL PREPARATIONS2 companies4.2%BIOTECHNOLOGY1 company2.1%MED PRODUCTS1 company2.1% About Derek ArchilaSenior Equity Research Analyst specializing in small- and mid-cap biotechnology companies, with a primary focus on immunology & inflammation (I&I), targeted oncology, and rare diseases. I am a key contributor to the #4 ranked Wells Fargo SMID-cap biotech franchise, and was individually recognized as a “Runner-Up” in the Institutional Investor (Extel) poll for Biotechnology Small & Mid-Cap Equity Research in both 2023 and 2024, ranking among the top 5 analysts in 2024.Follow on LinkedIn Derek Archila's Ratings History at Wells Fargo & Company Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsXFORX4 Pharmaceuticals7/10/2026Initiated Coverage$3.96$11.00Overweight$0.0000.00% ROIXFORX4 Pharmaceuticals7/10/2026Upgrade$4.41Strong-Buy$0.0000.00% ROIVRDNViridian Therapeutics6/29/2026Upgrade$19.00$31.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals6/15/2026Boost Price Target$88.38$155.00Overweight$0.0000.00% ROITRAXFirst Tracks Biotherapeutics6/8/2026Initiated Coverage$16.60$30.00Overweight$0.0000.00% ROINRIXNurix Therapeutics6/8/2026Downgrade$15.59$25.00Hold$0.0000.00% ROITRAXFirst Tracks Biotherapeutics6/8/2026Initiated Coverage$15.75$30.00Overweight$0.0000.00% ROIARGXargenex6/1/2026Boost Price Target$829.09$1,291.00Overweight$0.0000.00% ROIALMSAlumis5/15/2026Boost Price Target$24.63$51.00Overweight$0.0000.00% ROICABACabaletta Bio5/15/2026Boost Price Target$3.51$4.00Equal Weight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CLDXCelldex Therapeutics5/13/2026Boost Price Target$32.10$54.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S5/8/2026Lower Price Target$246.14$326.00Overweight$0.0000.00% ROIARGXargenex5/8/2026Boost Price Target$787.31$1,260.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals5/6/2026Boost Price Target$93.83$144.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals5/1/2026Boost Price Target$305.35$377.00Equal Weight$0.0000.00% ROISLNOSoleno Therapeutics4/17/2026Set Price Target$52.57$53.00Equal Weight$0.0000.00% ROIAPLSApellis Pharmaceuticals4/17/2026Downgrade$40.87$41.00Equal Weight$0.0000.00% ROISLNOSoleno Therapeutics4/17/2026Downgrade$52.78$53.00Equal Weight$0.0000.00% ROINRIXNurix Therapeutics4/9/2026Lower Price Target$15.80$28.00Overweight$0.0000.00% ROIVRDNViridian Therapeutics3/31/2026Lower Price Target$18.82$20.00Equal Weight$0.0000.00% ROIALXOALX Oncology3/19/2026Initiated Coverage$2.15$5.00Overweight$0.0000.00% ROIGLUEMonte Rosa Therapeutics3/18/2026Lower Price Target$16.03$29.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals3/12/2026Boost Price Target$90.02$143.00Overweight$0.0000.00% ROISEPNSepterna3/3/2026Boost Price Target$27.47$48.00Overweight$0.0000.00% ROIIRONDisc Medicine3/2/2026Boost Price Target$65.48$79.00Overweight$0.0000.00% ROIARGXargenex2/27/2026Lower Price Target$775.04$1,247.00Overweight$0.0000.00% ROISLNOSoleno Therapeutics2/27/2026Lower Price Target$38.88$110.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/27/2026Lower Price Target$93.22$136.00Overweight$0.0000.00% ROIIRONDisc Medicine2/17/2026Lower Price Target$55.99$78.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma2/13/2026Boost Price Target$74.58$98.00Overweight$0.0000.00% ROIINCYIncyte2/11/2026Lower Price Target$98.44$101.00Equal Weight$0.0000.00% ROIVRDNViridian Therapeutics2/3/2026Boost Price Target$33.20$29.00Equal Weight$0.0000.00% ROINRIXNurix Therapeutics1/29/2026Lower Price Target$17.87$29.00Overweight$0.0000.00% ROISLNOSoleno Therapeutics1/20/2026Reiterated Rating$42.48$114.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals1/20/2026Boost Price Target$101.63$145.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S1/20/2026Boost Price Target$205.83$330.00Overweight$0.0000.00% ROIINCYIncyte1/20/2026Reiterated Rating$106.21$107.00Equal Weight$0.0000.00% ROIBBIOBridgeBio Pharma1/20/2026Boost Price Target$76.86$88.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals1/20/2026Lower Price Target$19.97$26.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals1/20/2026Lower Price Target$348.61$376.00Equal Weight$0.0000.00% ROILouis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.Get the name and ticker of Louis Navellier's #1 AI stock freeARGXargenex1/20/2026Boost Price Target$798.13$1,317.00Overweight$0.0000.00% ROIINCYIncyte1/20/2026Downgrade$102.62$107.00Equal Weight$0.0000.00% ROIASNDAscendis Pharma A/S1/9/2026Boost Price Target$208.75$322.00Overweight$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Reiterated Rating$13.79$14.00Equal Weight$0.0000.00% ROIGLUEMonte Rosa Therapeutics1/8/2026Boost Price Target$25.37$30.00Overweight$0.0000.00% ROIVTYXVentyx Biosciences1/7/2026Downgrade$13.81Hold$0.0000.00% ROIALMSAlumis1/6/2026Boost Price Target$17.19$39.00Overweight$0.0000.00% ROIKYTXKyverna Therapeutics12/16/2025Boost Price Target$10.82$33.00Overweight$0.0000.00% ROINRIXNurix Therapeutics12/16/2025Boost Price Target$18.89$30.00Overweight$0.0000.00% ROIIRONDisc Medicine12/16/2025Boost Price Target$91.06$109.00Overweight$0.0000.00% ROIARGXargenex12/11/2025Boost Price Target$886.15$1,316.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics12/9/2025Boost Price Target$94.30$116.00Overweight$0.0000.00% ROIORICOric Pharmaceuticals12/8/2025Boost Price Target$11.00$25.00Overweight$0.0000.00% ROIINCYIncyte12/8/2025Boost Price Target$102.52$116.00Overweight$0.0000.00% ROIANNXAnnexon11/19/2025Boost Price Target$3.20$27.00Overweight$0.0000.00% ROISEPNSepterna11/14/2025Upgrade$19.24$28.00Overweight$0.0000.00% ROIORICOric Pharmaceuticals11/14/2025Lower Price Target$12.84$19.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma11/11/2025Boost Price Target$63.20$84.00Overweight$0.0000.00% ROIALNYAlnylam Pharmaceuticals11/11/2025Boost Price Target$444.86$479.00Equal Weight$0.0000.00% ROIGLUEMonte Rosa Therapeutics11/7/2025Boost Price Target$12.24$13.00Equal Weight$0.0000.00% ROIVTYXVentyx Biosciences11/7/2025Boost Price Target$8.60$14.00Overweight$0.0000.00% ROIARVNArvinas11/6/2025Lower Price Target$9.81$15.00Overweight$0.0000.00% ROISLNOSoleno Therapeutics11/5/2025Reiterated Rating$63.85$106.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics11/5/2025Boost Price Target$58.82$69.00Overweight$0.0000.00% ROIANABAnaptysBio11/5/2025Boost Price Target$36.13$81.00Overweight$0.0000.00% ROIKYTXKyverna Therapeutics10/29/2025Boost Price Target$7.82$31.00Overweight$0.0000.00% ROIINCYIncyte10/29/2025Boost Price Target$88.61$97.00Overweight$0.0000.00% ROINRIXNurix Therapeutics10/23/2025Lower Price Target$10.60$21.00Overweight$0.0000.00% ROIEXELExelixis10/21/2025Lower Price Target$34.54$30.00Equal Weight$0.0000.00% ROIKZRKezar Life Sciences10/17/2025Set Price Target$4.17$5.00Equal Weight$0.0000.00% ROIAPLSApellis Pharmaceuticals10/15/2025Initiated Coverage$23.15$32.00Overweight$0.0000.00% ROIKYTXKyverna Therapeutics10/8/2025Boost Price Target$5.41$27.00Overweight$0.0000.00% ROICCCCC4 Therapeutics9/23/2025Boost Price Target$2.61$10.00Overweight$0.0000.00% ROIATYRaTyr Pharma9/15/2025Reiterated Rating$1.05Equal Weight$0.0000.00% ROISLNOSoleno Therapeutics8/20/2025Initiated Coverage$66.81$123.00Overweight$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$21.24$38.00Overweight$0.0000.00% ROISTROSutro Biopharma8/12/2025Lower Price Target$7.73$30.00Equal Weight$0.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Reiterated Rating$190.35$295.00Overweight$0.0000.00% ROIZNTLZentalis Pharmaceuticals8/7/2025Lower Price Target$1.43$5.00Equal Weight$0.0000.00% ROIVRDNViridian Therapeutics8/7/2025Lower Price Target$16.71$26.00Equal Weight$0.0000.00% ROIARVNArvinas8/7/2025Lower Price Target$6.14$16.00Overweight$0.0000.00% ROIINCYIncyte8/6/2025Upgrade$77.72$89.00Overweight$0.0000.00% ROIARGXargenex7/31/2025Boost Price Target$670.33$756.00Overweight$0.0000.00% ROIINCYIncyte7/30/2025Boost Price Target$77.88$67.00Equal Weight$0.0000.00% ROIALMSAlumis7/25/2025Initiated Coverage$4.05$17.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals7/10/2025Boost Price Target$89.53$129.00Overweight$000.0000.00% ROIKYMRKymera Therapeutics6/26/2025Lower Price Target$44.98$53.00Overweight$000.0000.00% ROIATYRaTyr Pharma6/20/2025Boost Price Target$5.17$25.00Overweight$0.0000.00% ROIBPMCBlueprint Medicines6/17/2025Downgrade$128.16$129.00Hold$0.0000.00% ROIAPLSApellis Pharmaceuticals6/2/2025Boost Price Target$19.21$29.00Equal Weight$0.0000.00% ROIIran War Shock: What I Was Told In That Private Meeting (Ad)You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.Because THIS is the real reason.APLSApellis Pharmaceuticals5/8/2025Lower Price Target$17.90$26.00Equal Weight$00.0000.00% ROIARVNArvinas5/2/2025Lower Price Target$7.78$19.00Overweight$00.0000.00% ROIINCYIncyte4/30/2025Boost Price Target$61.16$59.00Equal Weight$00.0000.00% ROINRIXNurix Therapeutics4/9/2025Lower Price Target$9.86$25.00Overweight$00.0000.00% ROIRYTMRhythm Pharmaceuticals4/7/2025Boost Price Target$54.94$91.00Overweight$00.0000.00% ROIARVNArvinas3/12/2025Set Price Target$8.51$26.00Overweight$00.0000.00% ROIARGXargenex2/28/2025Boost Price Target$619.04$741.00Overweight$000.0000.00% ROIEXELExelixis2/24/2025Downgrade$36.85$36.00Equal Weight$00.0000.00% ROIANABAnaptysBio2/13/2025Boost Price Target$19.29$51.00Overweight$00.0000.00% ROIZNTLZentalis Pharmaceuticals1/30/2025Lower Price Target$1.66$6.00Equal Weight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftRaymond James FinancialStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
